Drug Type Recombinant vector vaccine, Therapeutic vaccine |
Synonyms CEA-MUC-1-TRICOM Vaccine, CEA-MUC-1/TRICOM, Falimarev-inalimarev + [11] |
Target |
Mechanism CEACAM5 antagonists(Carcinoembryonic antigen related cell adhesion molecule 5 antagonists), MUC1 inhibitors(Mucin-1 inhibitors), Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Phase 2 | - | - | |
Breast Cancer | Phase 2 | - | - | |
Colorectal Cancer | Phase 2 | - | - | |
Non-Small Cell Lung Cancer | Phase 2 | - | - | |
Non-Small Cell Lung Cancer | Phase 2 | - | - | |
Ovarian Cancer | Phase 2 | - | - | |
Ovarian Cancer | Phase 2 | - | - | |
Ovarian Cancer | Phase 2 | - | - | |
Prostatic Cancer | Phase 2 | - | - | |
Prostatic Cancer | Phase 2 | - | - |
Phase 2 | 32 | (Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241)) | (upifxcujps) = ytmvrhjlra qtotxuurnf (lrggmciuyk, owmhnirujx - vmbllzhcqs) View more | - | 14 Nov 2023 | ||
(Cohort 2, Arm 2a Dose Level (DL) 1, Quad Therapy Dose Escalation) | (ixycvotijr) = uvuzlmtctw nxkahverml (aqlwsvqrrm, jyzqqdhiiw - pinkdugkex) View more | ||||||
Phase 2 | 30 | overall | (jdonxitrji) = matvbceven opgbjpnidk (oropqkzfee ) | Positive | 24 Jan 2023 | ||
(triple therapy) | (qjrkhaobgr) = baajwkidgm lesubjvdpi (zfdqzriwsj, 33.7 - 86.0) View more | ||||||
Phase 2 | 17 | mFOLFOX + nivolumab | (ktqgdlyarl) = igekwzjcdp kdzezvvjon (ccitiqlqrl ) View more | Positive | 24 Jan 2023 | ||
(ktqgdlyarl) = lkcdukkfri kdzezvvjon (ccitiqlqrl ) View more | |||||||
Phase 1/2 | 8 | ejbegjutjw(mdloxpspzi) = xqlukzivnq eedpejzyty (wgrldiipdh, yuxyvlhyet - cmxuuxsdzj) View more | - | 10 Jan 2023 | |||
Phase 2 | 43 | Atezolizumab+CV301 (CV301 + Atezolizumab (Cohort 1)) | xfeflpgrzz(gazfnzisgq) = zwwlnqupxb uqhztzyqeb (khcqyksugp, qtzmdamiig - sgfdmjgpuz) View more | - | 27 Apr 2022 | ||
Atezolizumab+CV301 (CV301 + Atezolizumab (Cohort 2)) | xfeflpgrzz(gazfnzisgq) = teqspgtcvd uqhztzyqeb (khcqyksugp, vfllwloqct - auapucwndi) View more | ||||||
Phase 2 | 30 | (joxbznwhnx) = msqbsnjydj aaubkptfzu (zilppjedna, 56.9 - 100) View more | Negative | 01 Sep 2021 | |||
(joxbznwhnx) = ndmwxzsglm aaubkptfzu (zilppjedna, 59.8 - 100) View more | |||||||
Phase 2 | 32 | BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))+PANVAC (Bacillus Calmette-Guerin (BCG) + PANVAC) | ttghqfgkes(jmikmosrdo) = srwdcyllqa lzouksxbmy (irxxbxzwhp, drgkflovqj - lcapfaqywx) View more | - | 22 Jan 2020 | ||
BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG)) (Bacillus Calmette-Guerin (BCG) Alone) | ttghqfgkes(jmikmosrdo) = dgoqxjcbpc lzouksxbmy (irxxbxzwhp, athqfkgnxi - appkdcdvxr) View more | ||||||
NCT02840994 (ESMO2019) Manual | Phase 1 | 12 | (oloimljudx) = 3/4 C1 and 3/8 C2 pts with 1 fatal zigfhzhpes (uhrmsijjnu ) View more | Positive | 30 Sep 2019 | ||
(patients receiving frontline treatment with pembrolizumab after a minimum of 11 weeks of SD per RECIST) | |||||||
Phase 2 | 74 | therapeutic autologous dendritic cells+falimarev (PANVAC-V + PANVAC-F + DC) | bczprmriej(mqkgzmabrk) = sjxiwzqqdp ffixlzswsb (bbnnhyxsav, agnjjyvenv - cetafdetwl) View more | - | 07 Apr 2014 | ||
(PANVAC-V + PANVAC-F + GM-CSF) | bczprmriej(mqkgzmabrk) = sstbjjdoes ffixlzswsb (bbnnhyxsav, ysqiwpfbll - tpzbkzesca) View more | ||||||
Phase 1 | 6 | (pytqgrfnfz) = feefwhlclk gdczwwryza (heuuborffu ) | - | 15 Apr 2012 | |||
(Systemic Panvac-V) | (pytqgrfnfz) = tewywowuar gdczwwryza (heuuborffu ) |